MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx
Go back to MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx| MEDIWOUND (NASDAQ: MDWD) | Delayed: 13.12 -0.47 (3.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.59 | 52 Week High | $10.47 | |||
| Open | $13.60 | 52 Week Low | $5.10 | |||
| Day High | $13.60 | P/E | N/A | |||
| Day Low | $13.06 | EPS | $0.00 | |||
| Volume | 81,388 | |||||
